310 results
Page 3 of 16
6-K
EX-99
yikefanv
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
6-K
EX-10.1
ievqcqb
21 Sep 22
Current report (foreign)
8:00am
6-K
lejexua11fb8p8kh
21 Sep 22
Current report (foreign)
8:00am
424B5
e8avzyiiaz okya
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
8owq bfchj64h
19 Sep 22
BioLineRx Announces $15 Million Registered Direct Offering
8:08am
6-K
EX-99
k9hhiwl1nts3r1x7 2z
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-99
92e6lxutb9o dph6o
12 Sep 22
BioLineRx Announces Submission of New Drug Application
8:16am
6-K
EX-99
djcxky75i4yfxz0btzds
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
s99 4ezcybj
28 Jun 22
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in
7:14am
6-K
EX-99
zhstzz
16 Jun 22
BioLineRx Announces Appointment of Commercial Strategy
7:05am
6-K
EX-99
v8od6yut65fy kxlsv
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
nfjh18madu dnwg
16 Mar 22
BioLineRx Reports Fourth Quarter 2021 Financial Results
7:11am
6-K
EX-99
ki19nc8s 95c5k
3 Mar 22
BioLineRx Announces Additional Positive Results from
7:10am
6-K
EX-99
bte0t 103kwob2fr3
24 Jan 22
BioLineRx Announces Completion of Enrollment of Phase 1/2a
7:11am
6-K
EX-99
qtsz8i40r dvqiwzdli
18 Jan 22
BioLineRx Announces Successful Completion of Pre-NDA
7:11am
6-K
EX-99
hfjqu
17 Dec 21
BioLineRx Provides Highlights from Oral Presentation
7:10am
6-K
EX-99
ftugtl
15 Dec 21
BioLineRx Announces Formation of Immuno-Oncology
7:25am